Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.63 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215164 | 0.94 | BACE1 (0.64) | BACE1BACE2CYP3A4 | |
| SCHEMBL3507561 | 0.93 | BACE1 (0.60) | BACE1BACE2CYP3A4 | |
| SCHEMBL4216482 | 0.93 | BACE1 (0.66) | BACE1BACE2CYP3A4 | |
| SCHEMBL4210716 | 0.92 | BACE1 (0.59) | BACE1BACE2CYP3A4 | |
| SCHEMBL3511805 | 0.92 | BACE1 (0.61) | BACE1BACE2CYP3A4 | |
| SCHEMBL4204464 | 0.92 | BACE1 (0.61) | BACE1BACE2CYP3A4 | |
| SCHEMBL4208931 | 0.92 | BACE1 (0.62) | BACE1BACE2CYP3A4 | |
| SCHEMBL3510139 | 0.91 | BACE1 (0.60) | BACE1BACE2CYP3A4 | |
| SCHEMBL4219228 | 0.91 | BACE1 (0.60) | BACE1BACE2CYP3A4 | |
| SCHEMBL4222540 | 0.91 | BACE1 (0.60) | BACE1BACE2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CYP3A4 4540/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CYP3A4 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.